Pharmaceutical Executive Daily: FDA's new Fast-Track Review
In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.
3m Oct 03, 2025
3m
Pharmaceutical Executive Daily: President Trump Pauses Tariff Plan
Stay informed on key pharmaceutical news, including tariff updates, FDA shutdown risks, and insights from recent cell and gene therapy reviews.
3m Oct 02, 2025
3m
Pharmaceutical Executive Daily: Novo Nordisk Resubmits BLA for Awiqli
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy for primary humoral immunodeficiency, and Eli Lilly’s decision to halt development of a muscle-preserving weight-loss therapy.
3m Oct 01, 2025
3m
Pharmaceutical Executive Daily: September 30, 2025
In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to harmonize its global stock exchange listings, and reports that President Trump will announce a government-run direct-to-patient drug purchasing website.
3m Sep 30, 2025
3m
Pharmaceutical Executive Daily: September 29, 2025
In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of Regeneron’s Evkeeza for children with homozygous familial hypercholesterolemia.
2m Sep 29, 2025
2m
Pharmaceutical Executive Daily: September 26, 2025
In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the FDA’s approval of Eli Lilly’s Inluriyo for ESR1-mutated metastatic breast cancer, and President Trump’s call for steep tariffs on branded pharmaceuticals
3m Sep 26, 2025
3m
Pharmaceutical Executive Daily: September 25, 2025
In today’s Pharmaceutical Executive Daily, we cover Glenmark’s billion-dollar exclusive licensing deal with Hengrui, Harmony Biosciences’ trial setback for Zygel, and the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations.
3m Sep 25, 2025
3m
Pharmaceutical Executive Daily: September 24, 2025
In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.
3m Sep 24, 2025
3m
Pharmaceutical Executive Daily: September 23, 2025
In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete response letter to Otsuka and Lundbeck’s sNDA for Rexulti, and the medical community’s response to former President Trump’s claims linking Tylenol use to autism risk.
3m Sep 23, 2025
3m
Pharmaceutical Executive Daily: September 22, 2025
In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.
3m Sep 22, 2025
3m
Pharmaceutical Executive Daily: September 19, 2025
In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.
3m Sep 19, 2025
3m
Pharmaceutical Executive Daily: September 18, 2025
In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.
3m Sep 18, 2025
3m
Pharmaceutical Executive Daily: September 17, 2025
In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.
3m Sep 17, 2025
3m
Pharmaceutical Executive Daily: September 16, 2025
In today’s Pharmaceutical Executive Daily, we cover AbbVie’s stock jump following a Rinvoq litigation settlement, new insights into the ROI of specialty pharmacy adherence programs, and a closer look at what true innovation in PBM management entails.
3m Sep 16, 2025
3m
Pharmaceutical Executive Daily: September 15, 2025
3m Sep 15, 2025
3m
Pharmaceutical Executive Daily: September 12, 2025
Today's episode covers the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufacturers, and a White House plan to restrict treatments discovered in China.
2m Sep 12, 2025
2m
Pharmaceutical Executive Daily: September 11, 2025
In today’s Pharmaceutical Executive Daily, we cover Lundbeck’s restructuring affecting more than 600 international employees, Novo Nordisk’s global plan to cut 9,000 jobs, and former President Trump’s push to rein in pharmaceutical direct-to-consumer advertising.
3m Sep 11, 2025
3m
Pharmaceutical Executive Daily: September 9, 2025
In today’s Pharmaceutical Executive Daily, we explore strategies to strengthen pharma sales messaging, the role of AI-driven simulations in field rep training, and the FDA’s updated Green List restricting ingredients used in GLP-1 compounding.
3m Sep 09, 2025
3m
Pharmaceutical Executive Daily: September 8, 2025
2m Sep 08, 2025
2m
Pharmaceutical Executive Daily: September 5, 2025
In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.
3m Sep 05, 2025
3m
Pharmaceutical Executive Daily: September 4, 2025
In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.
3m Sep 04, 2025
3m
Pharmaceutical Executive Daily: September 3, 2025
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s response to political pressure over COVID-19 vaccine safety data, Cheryl Reicin’s outlook on future GLP-1 investment, and Novartis’ $5.2 billion acquisition of Argo Biopharmaceuticals.
2m Sep 03, 2025
2m
The Rx for High-Performance Leadership: Cutting Through the Chaos
In a turbulent era for biopharma, leadership demands clarity, resilience, and adaptability. In this candid podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, shares high-level insights on what CEOs can do to thrive amid the disruption—from regulatory agility to cultural resilience. The corporate strategy expert explains why the best leaders are the best le...
15m Aug 22, 2025
15m
Pharmaceutical Executive Weekly:CSL Cuts Jobs, Pfizer’s Sickle Cell Setback, and Eli Lilly Expands Zepbound Access
In this week’s Pharmaceutical Executive Weekly, we cover CSL’s decision to cut 15% of its U.S. workforce and close 22 plasma centers, Pfizer’s Phase 3 trial failure in sickle cell disease, and Eli Lilly’s new LillyDirect program expanding full-dose Zepbound access for obesity patients.
2m Aug 21, 2025
2m
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural ...
17m Apr 14, 2025
17m
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
In this Pharmaceutical Executive podcast epsiode, Peter Ax, Founder & CEO of UpScriptHealth, discusses:  The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts. How digital health platforms, like UpScriptHealth, can help reduce friction and costs in...
18m Mar 24, 2025
18m
The Misinformation Maze: Navigating Public Health in the Digital Age
In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, Chief Commercial Officer of Pleio, discusses: The threat of misinformation to public health and how emotional appeal plays a part Where patients are turning for trustworthy health information Strategies that can be used to verify information Pharma's role in helping to ensure patients have access to health insights they ...
24m Mar 11, 2025
24m
Navigating Distrust: Pharma in the Age of Social Media
In this episode of the Pharmaceutical Executive Podcast, CEO and Founder of Sooth, Ian Baer, is back to discuss:  The growing distrust in social media Why people trust friends and influencers over companies The EMA's departure from X Concerns about information accessibility The healthcare industry's trust gap "Dark Social" and SO MUCH MORE! Pharmaceutical Executive has a brand new look! Click...
27m Feb 18, 2025
27m
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence. By utilizing patient-level data and predictive modeling, AI can identify individual needs and preferences, tailoring interventions to optimize treatment outcomes. This personalized approach addresses the common challenges...
19m Feb 10, 2025
19m
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
In this episode of the Pharmaceutical Executive podcast, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok (mailto:https:/www.tiktok.com/@md.lawrence.werlin) ), discusses the challenges of addressing fertility misinformation on social media. He emphasizes the importance of providing accurate and reliable information and encourages patients to consult with healthc...
30m Jan 30, 2025
30m
Key Findings of the NIAGARA and HIMALAYA Trials
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer,...
13m Nov 08, 2024
13m
Fake Weight Loss Drugs: Growing Threat to Consumer Health
UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss: Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks What can be done to raise awareness among consumers about the dangers of counterfeit medications Ways increase access to legitimate weight loss medications, especially for those in underserved communities and much ...
21m Oct 25, 2024
21m
A Different Approach to Dermatology Care
Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is they're positioning to capitalize on the unmet needs in other specific therapeutic areas, their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.
15m Sep 23, 2024
15m
Beyond the Birthrate: The Societal Costs of Maternal Morality
In this episode of the Pharmaceutical Executive podcast, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses: The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make Specific eff...
16m Sep 06, 2024
16m
Empty Shelves, Urgent Solutions
Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts and the main factors that are contributing to the closures of both large and independent pharmacies, what alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities), some potential long term consequences if these pharmacy closures conti...
19m Aug 05, 2024
19m
The Weight-Loss Gold Rush: Legal and Regulatory Implications
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
17m Jul 11, 2024
17m
Healthcare Marketing Strategies for Reaching Diverse Audiences
Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more. Link to Honeycomb Health vide...
13m May 14, 2024
13m
A Decade in the Anti-Obesity Arena
Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.
23m Apr 30, 2024
23m
Fierce Females in the Life Science Space
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands. Featured in this episode are: Emma Banks, CEO, ramarketing Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas...
16m Mar 28, 2024
16m
Gen-Z Influence on Pharma M&A
Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z, and how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation.
21m Mar 14, 2024
21m
Recent Licensing Agreement Poised to Advance Company ADC
Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.
23m Jan 26, 2024
23m
Cell and Gene Therapy Check-in 2024
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
33m Jan 18, 2024
33m
Reshaping Pharmacovigilance in the age of AI
Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.
17m Jan 04, 2024
17m
Patient Centric Diabetes Care
Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more.
15m Dec 14, 2023
15m
DCT Opportunities in Clinical Research
Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.
29m Oct 26, 2023
29m
New FDA SaMD Guidance Will Bring Monumental Changes to Industry
David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.
11m Oct 12, 2023
11m
Venture Creation Firm Reveals Strategies For Launching New Companies & Forming Collaborations
In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company...
38m Sep 28, 2023
38m
Avoiding Commercialization Pitfalls for CGTs
Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices. In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT,...
31m Sep 14, 2023
31m
Ethical AI Practices
Gerald Kierce, co founder and CEO of Trustible and Andrew Gamino-Cheong, the company's CTO and co founder, delve into the realm of artificial intelligence discussing Trustible's mission and its pioneering efforts to ensure ethical AI use particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.
25m Aug 31, 2023
25m
Drug Pricing Challenges and Navigating The IRA
How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview: 1) the biggest drug pricing challenges today; 2) current efforts to lo...
39m Aug 17, 2023
39m